<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01626430</url>
  </required_header>
  <id_info>
    <org_study_id>A004/11</org_study_id>
    <nct_id>NCT01626430</nct_id>
  </id_info>
  <brief_title>Acute Effects of Tocotrienols on Insulin Sensitivity and Metabolic Risk Markers in Individuals at Risk for Metabolic Syndrome</brief_title>
  <official_title>Acute Effects of Tocotrienols on Insulinaemic and Inflammatory Responses in Metabolic Syndrome Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Malaysia Palm Oil Board</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Malaysia Palm Oil Board</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To compare the acute effects of gamma delta rich tocotrienol fractions (gd-TRF)
      on insulin sensitivity, metabolic risk markers and postprandial lipemia in individuals at
      risk for metabolic syndrome.

      Hypothesis: Gamma delta-rich TRF will improve insulin sensitivity, metabolic risk markers and
      postprandial lipemia in individuals at risk for metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised, double-blind, crossover trial will be undertaken to test the acute effects of
      supplementation of 200 mg, 400 mg gd-TRF vs. placebo. There are 3 occasions for subjects to
      attend during postprandial period and these occasions will be separated by at least one week.
      On the day preceding the postprandial high fat meal challenge, subjects will be asked to
      avoid food high in fat, alcohol, caffeine and taking part in any strenuous exercise. Subjects
      will be provided with a standardised low fat meal (containing &lt; 10 g fat) on the day
      preceding the postprandial study days to consume as their evening meal. They will be asked to
      fast overnight and instructed to avoid eating or drinking anything, except water, after 10
      pm. Fasting blood samples will be collected on the next day and subjects will then consume
      the test meal, containing 50 g test fat supplemented with gd-TRF. Further venous blood
      samples will be collected at regular intervals for up to 6 hours postprandially.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-peptide</measure>
    <time_frame>0, 15, 30, 60, 90, 120, 180, 240, 300, 360 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity (insulin, glucose)</measure>
    <time_frame>0, 5, 15, 30, 60, 90, 120, 180, 240, 300, 360 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-esterified fatty acid (NEFA)</measure>
    <time_frame>0, 5, 15, 30, 60, 90, 120, 180, 240, 300, 360 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triglycerides (TAG)</measure>
    <time_frame>0, 60, 120, 180, 240, 300, 360 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers (IL-6, IL-1β, TNF-α)</measure>
    <time_frame>0, 120, 240, 360 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBMC nuclear factor-κappa B (NF-κB)</measure>
    <time_frame>0, 240, 360 min</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>200 mg gd-TRF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg gd-TRF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gamma delta TRF</intervention_name>
    <description>50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.</description>
    <arm_group_label>200 mg gd-TRF</arm_group_label>
    <arm_group_label>400 mg gd-TRF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 20-60 years

          -  BMI ≥ 25 kg/m2

          -  Elevated triacylglycerols ≥ 1.70 mmol/L

          -  Low HDL cholesterol &lt; 1.04 mmol/L (men), &lt; 1.30 mmol/L (women)

          -  Elevated blood pressure ≥ 130/ ≥ 85 mmHg

          -  Fasting plasma glucose ≥ 5.60 - 7.00 mmol/L

          -  Increased waist circumference ≥ 90 cm (men), ≥ 80 cm (women)

        Exclusion Criteria:

          -  BMI ≤ 18.5 kg/m2

          -  Current use of antihypertensive or lipid lowering, insulin/glucose modulating
             medication

          -  Lactose/milk intolerance

          -  Alcohol intake exceeding a moderate intake (&gt; 28 units per week)

          -  Smoker

          -  Pregnancy or lactation

          -  Fever, cold and infection during bleeding day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Teng Kim Tiu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Malaysia Palm Oil Board</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Malaysian Palm Oil Board (MPOB)</name>
      <address>
        <city>Kajang</city>
        <state>Selangor Darul Ehsan</state>
        <zip>43000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malaysia Palm Oil Board</name>
      <address>
        <city>Kajang</city>
        <state>Selangor</state>
        <zip>43000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2012</study_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gamma delta TRF</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Postprandial lipaemia</keyword>
  <keyword>Inflammatory markers</keyword>
  <keyword>NF-κB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

